Skip to main content
California Medicine logoLink to California Medicine
. 1970 May;112(5):32–37.

The Hyperlipoproteinemias—A Simplified Classification and Approach to Therapy

Robert Zelis, Dean T Mason, James F Spann Jr
PMCID: PMC1501269  PMID: 4924875

Abstract

It is now clear that the various hyperlipidemias represent a heterogenous group of disorders, each having various clinical and laboratory characteristics, prognosis and treatment. The three disorders commonly associated with premature atherosclerotic vascular disease are Type II (hyperbetalipoproteinemia), Type III (“broad beta” or “floating beta” disease) and Type IV (hyperprebetalipoproteinemia or, endogenous hypertriglyceridemia).

The diagnosis of each of these three disorders can be suggested by the fasting serum cholesterol level and the appearance of the fasting serum after it has remained overnight in a refrigerator. Type II disease is characterized by a clear serum and a pronounced to moderate hypercholesterolemia. It is treated by reducing dietary cholesterol and saturated fats, increasing dietary polyunsaturated fats, and cholestyrmine. Type IV disease is characterized by a turbid serum indicating hypertriglyceridemia and a normal or only slightly elevated serum cholesterol level. It is treated with weight reduction, a low carbohydrate diet and clofibrate. Type III disease is characterized by both a turbid serum and increased cholesterol levels. It is treated with weight reduction, a low cholesterol diet and clofibrate.

With the treatment of all disorders the lipid values should improve; however, with the treatment of Type III disorder both triglyceride and cholesterol levels return to normal, xanthoma resorb and there is an improvement in the peripheral blood flow, indicating that there has been amelioration of the atherosclerotic process.

Full text

PDF
34

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dayton S., Pearce M. L., Goldman H., Harnish A., Plotkin D., Shickman M., Winfield M., Zager A., Dixon W. Controlled trial of a diet high in unsaturated fat for prevention of atherosclerotic complications. Lancet. 1968 Nov 16;2(7577):1060–1062. doi: 10.1016/s0140-6736(68)91531-6. [DOI] [PubMed] [Google Scholar]
  2. Epstein F. H. The epidemiology of coronary heart disease. A review. J Chronic Dis. 1965 Aug;18(8):735–774. doi: 10.1016/0021-9681(65)90017-2. [DOI] [PubMed] [Google Scholar]
  3. Fredrickson D. S., Levy R. I., Lees R. S. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967 Feb 2;276(5):273–concl. doi: 10.1056/NEJM196702022760507. [DOI] [PubMed] [Google Scholar]
  4. HOLLING H. E., BOLAND H. C., RUSS E. Investigation of arterial obstruction using a mercury-in-rubber strain gauge. Am Heart J. 1961 Aug;62:194–205. doi: 10.1016/0002-8703(61)90318-0. [DOI] [PubMed] [Google Scholar]
  5. Heinle R. A., Levy R. I., Frederickson D. S., Gorlin R. Lipid and carbohydrate abnormalities in patients with angiographically documented coronary artery disease. Am J Cardiol. 1969 Aug;24(2):178–186. doi: 10.1016/0002-9149(69)90401-9. [DOI] [PubMed] [Google Scholar]
  6. Kannel W. B., Castelli W. P., McNamara P. M. The coronary profile: 12-year follow-up in the Framingham study. J Occup Med. 1967 Dec;9(12):611–619. [PubMed] [Google Scholar]
  7. Kuo P. T. Current metabolic-genetic interrelationship in human atherosclerosis, with therapeutic considerations. Ann Intern Med. 1968 Feb;68(2):449–466. doi: 10.7326/0003-4819-68-2-449. [DOI] [PubMed] [Google Scholar]
  8. Levy R. I., Fredrickson D. S. Diagnosis and management of hyperlipoproteinemia. Am J Cardiol. 1968 Oct;22(4):576–583. doi: 10.1016/0002-9149(68)90165-3. [DOI] [PubMed] [Google Scholar]
  9. WHITNEY R. J. The measurement of volume changes in human limbs. J Physiol. 1953 Jul;121(1):1–27. doi: 10.1113/jphysiol.1953.sp004926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Zelis R., Mason D. T., Barth W. Abnormal peripheral vascular dynamics in systemic amyloidosis. Ann Intern Med. 1969 Jun;70(6):1167–1172. doi: 10.7326/0003-4819-70-6-1167. [DOI] [PubMed] [Google Scholar]
  11. Zelis R., Mason D. T., Braunwald E. A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. J Clin Invest. 1968 Apr;47(4):960–970. doi: 10.1172/JCI105788. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from California Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES